Vioxx Research Biased, Journal Says
Two recent reports published by the Journal of the American Medical Association allege Merck & Co. misrepresented research conducted on its arthritis painkiller Vioxx.
Two recent reports published by the Journal of the American Medical Association allege Merck & Co. misrepresented research conducted on its arthritis painkiller Vioxx.
Lawyers for individuals seeking early payment from the multi-billion dollar Vioxx settlement have been granted an extra month to submit their paperwork.
The U.S. Justice Department announced Thursday that pharmaceutical company Merck & Co. has agreed to pay over $650 million to settle claims that the drug maker paid illegal kickbacks to health care providers while defrauding federal health care programs.
A federal grand jury is investigating the allegation that Merck & Co. promoted the arthritis drug Vioxx for uses that had not been approved by the FDA, according to The Wall Street Journal.
The maker of Vioxx announced Friday it will pay $4.85 billion to settle thousands of lawsuits claiming that the drug caused stroke and heart failure in many users.
The New Jersey Supreme Court will hear arguments today regarding a proposed class-action lawsuit concerning patients who took the arthritis drug Vioxx before it was recalled from shelves in September 2004.
Five people in Madison County filed a 27-count complaint earlier this month alleging that they suffered heart attacks, strokes, and financial damages as a result of taking the pain-reliever Celebrex.
A Madison County woman has filed suit against Pfizer, the maker of Bextra, alleging that she suffered a heart attack as a result of taking the drug for more than six months.
Merck, the company responsible for manufacturing the controversial arthritis drug Vioxx, is seeking FDA approval on a new arthritis medicine called Arcoxia.
The burden of over 15,000 Vioxx cases is taking a toll on the Atlantic County Civil Courthouse, depleting available filing cabinets and jury pools simultaneously.
Panel of judges overturns earlier decision, instructs lower court to reconsider potential for class-action suit by plaintiffs seeking to have tests for heart ailments paid for by the manufacturers of Vioxx.
A Vioxx-litigation plaintiff received good and bad news recently as a Texas court upheld a previous ruling that found the company liable for her husband’s death, though it reduced the reward according to state law.
Researchers have discovered a previously undiscovered effect of COX-2 inhibitors that may explain the apparent increased risk of heart attack and stroke in patients taking Vioxx and other similar medications.
Quebec has become the first North American jurisdiction to allow a consumer class-action lawsuit against the maligned pharmaceutical company.
The Atlantic County court system is bogged down by the thousands of lawsuits filed against Merck & Co. in the pharmaceutical giant's home state of New Jersey.
According to researchers at the Boston Collaborative Drug Surveillance Program, a link has been discovered between the anti-inflammatory medication diclofenac and an increased risk of heart attacks.
In yet another setback for the makers of Vioxx, a New Jersey Superior Court judge recently ruled that evidence discovered since a November trial is sufficient to overturn the verdict issued in Merck's favor.
Last week a New Orleans jury ordered pharmaceutical giant Merck & Co. to pay $51 million to man who suffered a heart attack after taking the drug Vioxx.
Merck & Co. finds itself in the crosshairs of another Vioxx lawsuit as California’s first trial over the controversial painkiller gets underway on Tuesday.
Ever since the lawsuits started rolling in, Merck and their lawyers have maintained the assertion that the popular arthritis painkiller Vioxx was only dangerous to patients who took the drug for at least 18 months.
WASHINGTON - In the midst of several of the nation's largest pharmaceutical lawsuits, the FDA has been slow to detect safety problems in drugs already on the market and in responding to potential dangers, a federal study concludes.
FORT MYERS, Fla. - Merck & Co. is facing another litigious nightmare and may need to hire additional attorneys to challenge a new lawsuit alleging the drug company was negligent in its handling of the osteoporosis drug Fosamax.
U.S. stocks fell on Thursday amid disappointing March retail sales, high crude oil prices, and another legal setback for drug giant Merck & Co.
In another devastating blow to Merck, a New Jersey jury has determined that the company did not effectively warn patients of the dangers of the drug Vioxx, which resulted in the heart attack of John McDarby.
ATLANTIC CITY, New Jersey - Merck & Co. finished up its defense in the latest of a string of Vioxx product liability trials with expert testimony from a psychiatrist.
SACRAMENTO, Calif.- In response to public outcry over recent prescription drugs scandals, California Public Interest Research Group (CALPIRG) and Senator Jack Scott (D-Altadena) have introduced legislation that would give the public unprecedented access to information on pharmaceutical clinical trials.
New Orleans, La. -- Jurors began deliberations Friday in the retrial of the nation's first federal Vioxx court case, which previously resulted in a hung jury.
Rio Grande City, TX -- The attorneys representing the family of Leonel Garza opened their case Wednesday, contending that the man's death was due to a heart attack caused by Merck's popular painkiller Vioxx.
Rio Grande, Texas -- The nation's fourth Vioxx trial, pitting the family of Leonel Garza against pharmaceutical giant Merck & Co., is set to commence this week.
Atlantic City, New Jersey -- The defense attorneys representing Merck & Co. rested their case Thursday after presenting a final expert witness.
Atlantic City, NJ -- The evidence presented by Merck & Co.'s first witness was thrown out Friday by the judge presiding over the nation's second Vioxx trial.
Atlantic City, New Jersey -- The attorneys for the plaintiff rested their case in the civil product liability trial against Merck & Co. on Wednesday.
Atlantic City, NJ -- Frederick "Mike" Humeston, a decorated Vietnam War veteran, took the stand Wednesday to testify against Merck & Co. in his lawsuit against the Vioxx manufacturer.
Atlantic City, NJ -- The former president of Merck Research Laboratories revealed concerns he had regarding the safety of Vioxx in a previously recorded deposition played in court yesterday.
Atlantic City, New Jersey -- A witness for the plaintiff in the case Humeston v. Merck & Co. testified Monday, contending that even one dose of Vioxx could be enough to trigger a heart attack
Atlantic City, NJ -- Lawyers for plaintiff Mike Humeston and defendant Merck & Co. took turns presenting opening arguments during the nation's second Vioxx court case on Wednesday.
The nation's second Vioxx court case, pitting plaintiff Frederick Humeston against defendant Merck & Co., began with jury selection on Monday, September 12.
Trenton, New Jersey -- The nation's second Vioxx court case, brought by a decorated Vietnam War veteran, is set to begin September 12 in Atlantic City.
A spokesman for Merck & Co. indicated that the pharmaceutical manufacturer would consider settling some of the pending Vioxx cases leveled against it.
Portland, Oregon -- The State Treasurer sued Merck & Co., Inc. last week, alleging that the pharmaceutical giant failed to disclose risks associated with its popular painkiller Vioxx.
Angleton, Texas -- A jury decided against Merck & Co. on Friday, ruling for the plaintiff in the United State's first Vioxx trial.
Montgomery, Alabama -- A U.S. District Court judge announced that the first federal Vioxx Multi-district Litigation will go to trial in late November.
New York -- The Senate Majority Leader suggested that pharmaceutical companies voluntarily impose a two-year ban on direct-to-consumer advertising.
July 30 -- A State Superior Court Judge in New Jersey decided to certify a class action suit brought against Merck & Co. for damages associated with Vioxx.
On July 22, a doctor told a packed courtroom that he had resisted prescribing Vioxx to his patients because he did not believe the arthritis drug was safe.
The widow of Robert Ernst, a man who died from heart problems in 2001, blames Merck & Co. Inc. for his sudden death. Carol Ernst's lawsuit against the pharmaceutical company will be the first of thousands of Vioxx related cases to go to court.
A physician's group filed a lawsuit on behalf of a Minnesota woman, claiming that Merck inappropriately used results from animal studies to counter evidence that Vioxx was harmful to humans.
Angleton, Texas - The head of the Merck & Co.'s epidemiology department testified on Monday in the nation's first Vioxx case to go to trial.
The first Vioxx case to go to court got underway in Angleton, Texas on Thursday, with both sides presenting opening arguments to jurors.
In Angleton, Texas, approximately 120 people filled out questionnaires to be considered for jury duty in the first Vioxx lawsuit to go to trial in the United States.
The state of Texas is suing the manufacturer of Vioxx, an arthritis medication that was recently recalled due to research indicating that it may increase the risk of heart attack and stroke.
Approximately 50 French citizens are joining a US lawsuit against Merck & Co., Inc. the manufacturer of Vioxx. The plaintiffs claim that they suffered heart problems while taking the prescription painkilling medication.
On Tuesday, July 5, a state district judge in Wharton, Texas refused to postpone the first Vioxx trial, as per the defense's request. Lawyers for Merck & Co., the pharmaceutical giant being sued in the wrongful death case, claimed that potential jurors would be biased because of publicity before the trial.
The U.S. Food and Drug Administration diligently regulates and monitors the dangers of prescription and non-prescription drugs in America. And every year the FDA forces drug manufacturers to recall hundreds of medications from pharmacy shelves.
On September 30, 2004, Merck & Co Inc. voluntarily pulled the popular arthritis medication Vioxx® from the market after studies proved that it doubled users’ risk of heart attack and stroke.
©2008 Einstein Law All Rights Reserved